

In the claims:

Please amend claims 1, 29, 36 and 37 as follows:

Sub 2
B'
1. (Amended) A method of treating an immune-mediated disorder having an inflammatory component and/or a cellular hyperproliferation component, comprising the step of administering to a patient requiring such treatment a gold compound and at least one corticosteroid, wherein the at least one corticosteroid is selected to interact with the gold compound to exhibit preferential synergistic action towards one of the components of said disorder or to exhibit equal action towards each component of said disorder, provided that said method does not include the administration of a combination of auranofin and betamethazone dipropionate.

Sub 4
B
29. (Amended) A pharmaceutical composition comprising a gold compound and one or more corticosteroids, the corticosteroid being selected to interact with the gold compound to exhibit a preferential synergistic action towards an inflammatory component and/or a cellular hyperproliferation component of an immune-mediated disorder, in combination with a pharmaceutically acceptable carrier, excipient, adjuvant or solvent, provided that said composition does not include auranofin and betamethazone dipropionate.

m
B
36. (Amended) A pharmaceutical composition according to claim 35 wherein the corticosteroid is selected from the group consisting of hydrocortisone, betamethasone dipropionate, mometasone furoate and fluocinolone acetonide.

37. (Amended) A pharmaceutical composition according to claim 29, wherein the gold compound is auranofin.